Aandeel IVCPU SWIFTMERGE ACQUISITION CORP.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Swiftmerge Acquisition Corp. Nasdaq

Aandelen

IVCPU

KYG638361298

Beurs gesloten - Nasdaq
Andere beurzen
 22:30:01 03-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
10,8 USD +4,55% Intraday-grafiek van Swiftmerge Acquisition Corp. +4,55% +0,75%
01/04 Swiftmerge Acquisition Corp. Rapporteert winstresultaten voor het volledige jaar eindigend op 31 december 2023 CI
2023 Swiftmerge Acquisition Corp. Rapporteert de winst over het derde kwartaal en de negen maanden eindigend op 30 september 2023 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Swiftmerge Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Swiftmerge Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Swiftmerge Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Swiftmerge Acquisition : Non-Reliance on Previously Issued Financial Statements or Related Audit Report or Completed Interim Report - Form 8-K
Swiftmerge Acquisition Signs Merger Deal to Take HDL Therapeutics Public
HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.
SWIFTMERGE ACQUISITION CORP. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
Swiftmerge Acquisition : Adjournment of Extraordinary General Meeting - Form 8-K
Swiftmerge Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment
HDL Therapeutics, Inc. signed a non-binding letter of intent to acquire Swiftmerge Acquisition Corp. in a reverse merger transaction.
SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
SWIFTMERGE ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Swiftmerge Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
Swiftmerge Acquisition Corp. Auditor Raises 'Going Concern' Doubt
Swiftmerge Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Swiftmerge Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers IVCP
  4. Koers IVCPU
  5. Nieuws Swiftmerge Acquisition Corp.
  6. Andere talen